

Jul 2, 2014

**Notification of the Noven Pharmaceuticals, Inc. assigns rights for
Lithobid[®](lithium carbonate tablets)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; President and CEO: Hirotaka Nakatomi, hereinafter referred to as “Hisamitsu”) hereby announces that Noven Pharmaceuticals, Inc. (Head Office: Florida, U.S.A.; hereinafter referred to as “Noven”) has entered into an agreement with ANI Pharmaceuticals, Inc. (Head Office: Minnesota, U.S.A.; hereinafter referred to as “ANI”) to assign rights of approval for manufacture and commercial for Lithobid[®](lithium carbonate tablets) to ANI.

Under this agreement, Noven will transfer its rights of approval for manufacture and commercial in the United States to ANI, and Noven will receive \$12million including an \$11 million upfront payment and a \$1 million future milestone payment from ANI.

Financial impacts of this event to the consolidated results of operations isn't expected to be material, it is no change of the earnings forecast for FY02/2015.

About Noven

Noven is a pharmaceutical company engaged in research, development, manufacturing, marketing, and sale of pharmaceutical products. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers, and its industry partners. Noven is a subsidiary of Hisamitsu and serves as Hisamitsu's U.S. growth platform.